SYMPHONY: Synergistic Immuno Photothermal Nanotherapy

Unmet Need

Metastatic spread results in more than 90 percent of cancer deaths, and current therapeutic options, such as systemic chemotherapy, are often ineffective with harsh side effects. In recent years, immunotherapy using specific immune checkpoint modulators has provided a promising way to disrupt the tumor immunosuppressive environment. However, current immunotherapy methods employ antibodies that are effective only for a limited number of patients and can become ineffective over time. Therefore, it would be of great clinical significance to develop a method capable of broadening and stabilizing the effect of immunotherapy using a safe and effective synergistic combination treatment approach to achieve a long-term therapeutic effect and produce long-lasting effect for an extended patient population.

Technology

Duke inventors have reported a method for treating metastatic cancer called SYMPHONY (Synergistic Immuno Photothermal Nanotherapy). This is a novel two-pronged modality that has the potential to safely eradicate both primary tumors and distant metastatic foci. Using a combination of anti-PD-L1 immunotherapy and biologically compatible plasmonic gold nanostar (GNS)–mediated photothermal therapy, the inventors were able to achieve complete eradication of laser-treated primary tumors as well as untreated distant tumors in mice implanted with the MB49 bladder cancer cells. Delayed rechallenge with MB49 cancer cells injection in mice that were cured by SYMPHONY did not lead to new tumor formation after 60 days observation, indicating that SYMPHONY treatment induced effective long-lasting immunity like an ‘anticancer vaccine effect’ against MB49 cancer cells.

Advantages

  • A rapid, safe, and effective cancer treatment
  • Can trigger a powerful thermally enhanced systemic immune activation to rapidly eradicate locally aggressive as well as distant metastatic cancer
  • Shows clear improvement over anti-PD-L1 therapy alone for cancer treatment of both primary tumors and distant metastasis
SYMPHONY: Synergistic Immuno Photothermal Nanotherapy. By disabling the tumor immune resistance using anti-PD-L1 antibodies and simultaneously ablating individual cancer cells using GNS-enabled photothermal therapy, SYMPHONY can trigger a powerful thermally enhanced systemic immune activation to rapidly eradicate locally aggressive as well as distant metastatic cancer. Figure 1 from Liu, Y., Maccarini, P., Palmer, G.M. et al. Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers. Sci Rep 7, 8606 (2017). https://doi.org/10.1038/s41598-017-09116-1. To view copy of license:  http://creativecommons.org/licenses/by/4.0/.

Duke File (IDF) Number

T-004628

Inventor(s)

  • Vo-Dinh, Tuan
  • Inman, Brant
  • Liu, Yang
  • Maccarini, Paolo
  • Palmer, Greg
  • Weitzel, Douglas

Patents

    • Patent Number: 11,260,128
    • Title: SYNERGISTIC NANOTHERAPY SYSTEMS AND METHODS OF USE THEREOF
    • Country: United States of America
    • Patent Number: 11,260,128
    • Title: SYNERGISTIC NANOTHERAPY SYSTEMS AND METHODS OF USE THEREOF
    • Country: United States of America
    • Patent Number: 11,260,128
    • Title: SYNERGISTIC NANOTHERAPY SYSTEMS AND METHODS OF USE THEREOF
    • Country: United States of America

For more information please contact

College

Pratt School of Engineering